Select Page

WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell quarterly update, effective December 21, 2020.